Log In
Copyright © 2006 American Chemical Society
August 7, 2006 Cover
Volume 84, Issue 32
Volume 84, Issue 32
TARGETINGBREAST CANCER
By targeting multiple HER-family receptors, small-molecule drugs could fill the therapeutic gaps left by Herceptin
Credit: Seattle Times/ News Com
» Full Article
August 7, 2006 Issue
Volume 84, Issue 32
August 7, 2006 Issue, Vol. 84 | Iss. 32
By targeting multiple HER-family receptors, small-molecule drugs could fill the therapeutic gaps left by Herceptin
(pp. 21-27)
Features
Career & Employment
Chemists' starting salaries are up a notch from 2004, but employment scene remains below par (pp. 57-64)
News of the Week
The Next Step In Obesity Vaccines
Ghrelin vaccine permits male rats to gain less weight on usual diet
(p.15)Senate Approves Offshore Drilling
Chemical makers say bill could provide new supplies of natural gas and lower prices
(p.16)Departments
Business
The European Union explores ways to make it easier for cartel victims to recover damages
(pp. 31-32)
Newly independent from Total, Arkema pushes to boost performance, raise profits
(pp. 34-35)
Companies should end quarterly earnings guidance and focus on long term, business group says
(p.36)Concentrates
(pp. 28-29)
(pp. 28-29)- Hemlock seeks new polysilicon site
- Probe of rubber cartel concludes
- Basell slates two new plants
- Dow looks at desalination technology
- Amgen licenses Predix drugs
- Cytec, DSM end partnership
- Hexion sells plastics unit
- Onyx expands its kilo labs
- Lanxess backs ultramarathoner
- Bayer boosts MDI production
- Nuvelo revises Archemix deal
- NPIL invests in potent drugs
- AstraZeneca ups portfolio
- Chemical prices are still soaring
- Business Roundup
Government & Policy
Congressionally legislated programs and projects circumvent traditional competitive grant process
(p.30)
Science & Technology
Artificial injections of sulfur into the stratosphere would cool Earth, scientist suggests
(p.19)
Beefing up signal of FRET kinase biosensors makes inexpensive high-throughput screening possible
(pp. 48-49)
By targeting multiple HER-family receptors, small-molecule drugs could fill the therapeutic gaps left by Herceptin
(pp. 21-27)Career & Employment
Chemists' starting salaries are up a notch from 2004, but employment scene remains below par
(pp. 57-64)